| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Cell division cycle protein 27 homolog;Anaphase-promoting complex subunit 3;APC3;CDC27 homolog;CDC27Hs;H-NUC;CDC27;ANAPC3, D0S1430E, D17S978E; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human Myosin VIIa Myosins |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-MYO7A antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AFCH-13; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-MYO7A Monoclonal Antibody catalog # M03915. Tested in WB, IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: MYO7A (Cell division cycle protein 27 homolog).
- Antibody format: Monoclonal; clone AFCH-13; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
MYO7A (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. . Reported cellular localization context: Nucleus. Tissue expression notes (as provided): Abundantly expressed in brain, heart and pancreas, and at lower levels in kidney and placenta. Up-regulated in the lumbar spinal cord from patients with sporadic amyotrophic lateral sclerosis (ALS) compared with controls, with highest levels of expression in individuals with predominant lower motor neuron involvement. .
Research relevance and current trends
- Research context keywords from the source record include: Cytoskeleton,Cytoskeleton/ECM,Motor Proteins,Myosin,Signal Transduction.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
Workflow ideas (metafield): Validate MYO7A antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect MYO7A expression by Western blot in cell or tissue lysates, Detect MYO7A in FFPE tissue sections by immunohistochemistry, Localize MYO7A by immunofluorescence/immunocytochemistry in cultured cells, Quantify MYO7A-positive cells by flow cytometry in single-cell suspensions
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 13 kDa; calculated MW: 91867 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 13 kDa
- Cellular localization (provided): Nucleus.
- Tissue details (provided): Abundantly expressed in brain, heart and pancreas, and at lower levels in kidney and placenta. Up-regulated in the lumbar spinal cord from patients with sporadic amyotrophic lateral sclerosis (ALS) compared with controls, with highest levels of expression in individuals with predominant lower motor neuron involvement. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
